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Anthracycline antibiotics non-covalently incorporated into the block
copolymer micelles: in vivo evaluation of anti-cancer activity
EV Batrakoval 3, TY Dorodnychl 2, EY Klinskii1'4, EN Kliushnenkoval, OB Shemchukoval,
ON Goncharoval, SA Arjakov2, VY Alakhov" 4 and AV Kabanovl 3
'Moscow Institute ofBiotechnology, Inc., and Russian Research Center ofMolecular Diagnostics and Therapy, Simpheropolskii
blvd. 8, Moscow 113149, Russia; 2Department ofPolymer Science, Faculty ofChemistry, MVLomonosov Moscow State University,
Vorobievy Gory, Moscow 119899 GSP, Russia.
Summary The chemosensitising effects of poly(ethylene oxide)-poly(propylene oxide)-poly-(ethylene oxide)
(PEO-PPO-PEO) block copolymers (Pluronic) in multidrug-resistant cancer cells has been described recently
(Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV 1996, Biocon. Chem., 7, 209). This paper presents
initial studies on in vivo evaluation of Pluronic copolymers in the treatment of cancer. The anti-tumour activity
of epirubicin (EPI) and doxorubicin (DOX), solubilised in micelles of Pluronic L61, P85 and F108, was
investigated using murine leukaemia P388 and daunorubicin-sensitive Sp2/0 and -resistant Sp2/0DNR myeloma
cells grown subcutaneously (s.c.). The study revealed that the lifespan of the animals and inhibition of tumour
growth were considerably increased in mice treated with drug/copolymer compositions compared with animals
treated with the free drugs. The anti-tumour activity of the drug/copolymer compositions depends on the
concentration of the copolymer and its hydrophobicity, as determined by the ratio of the lengths of hydrophilic
PEO and hydrophobic PPO segments. The data suggest that higher activity is associated with more
hydrophobic copolymers. In particular, a significant increase in lifespan (TIC> 150%) and tumour growth
inhibition (>90%) was observed in animals with Sp2/0 tumours with EPI/P85 and DOX/L61 compositions.
The effective doses of these compositions caused inhibition of Sp2/0 tumour growth and complete
disappearance of tumour in 33-50% of animals. Future studies will focus on the evaluation of the activity
of Pluronic-based compositions against human drug-resistant tumours.
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Various drug delivery systems are actively being developed
to decrease toxicity and increase the activity of chemother-
apeutic agents. Examples are antibodies (Reilly, 1995),
liposomes (Mayer et al., 1995; Gabizon, 1993), polymer-
drug conjugates (Maeda et al., 1992; Duncan, 1992), and
microspheres (Doughty et al., 1995). Micelles of block
copolymers, containing hydrophilic and hydrophobic chain
segments, have recently attracted considerable attention as a
novel class of drug delivery systems (Bader et al., 1984;
Kabanov et al., 1989; Yokoyama et al., 1990). These
micelles represent self-assembled structures with a core
formed by the hydrophobic segments and a corona formed
by the hydrophilic segments. A great variety of drugs can be
non-covalently incorporated into such micelles by simple
mixing with the block copolymer solutions (Kabanov et al.,
1992). Drug molecules can also be covalently linked to the
repeating units of the copolymer segment (Bader et al.,
1984). In both cases, the drug incorporates into the micelle
core, where it is masked from the external media by the
hydrophilic corona, which usually consists of non-toxic and
non-immunogenic poly(ethylene oxide) (PEO) chains. As a
result, the metabolic stability of such drugs, for example
doxorubicin, can be greatly increased (Yokoyama et al.,
1991). The PEO corona also produces micelles with long
circulation times in the body similar to the 'stealth'
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liposomes with PEO-modified surface (Torchilin et al.,
1994). The size of the micelles is similar to that of viral
particles (below 50 nm), so that they are much smaller than
most other self-assembled delivery systems. This presumably
provides for improved penetration of tissues (Kabanov et
al., 1992). Finally, the copolymer structure allows easy
attachment of vector molecules, such as antibodies, to the
end groups of PEO segments, allowing targeting of these
systems in vivo (Kabanov et al., 1992).
Most early work in this area concentrated on drugs that
were covalently conjugated to a PEO-polypeptide copolymer
(Bader et al., 1984; Yokoyama et al., 1990, 1991). Recently,
these studies shifted to the systems in which the drug is non-
covalently incorporated in the micelles (Trubetskoy et al.,
1994; Dunn et al., 1994; Draper et al., 1995; Kwon et al.,
1993, 1995; La et al., 1996). In contrast to the conjugates,
these systems retain the drug by hydrophobic interactions
permitting easy release into the cell. They were first used to
target a central nervous system (CNS) agent, haloperidol,
across the blood-brain barrier to the brain (Kabanov et al.,
1989, 1992). In this work the drug was solubilised in Pluronic
micelles coupled to targeting antibodies. This approach
resulted in an increase in in vivo neuroleptic activity several
hundred-fold. Another striking result was obtained during a
study of the Pluronic effects on the activity of antineoplastic
agents in multidrug-resistant (MDR) cancer cells, expressing
the P-glycoprotein (P-gp) drug efflux pump (Alakhov et al.,
1996a,b). It was found that the copolymers 'hypersensitise'
the resistant cells, with the result that the cytotoxic drug
activity was increased by about three orders of magnitude.
Drug transport data suggest that MDR reversal in the
presence of these copolymers involves inhibition of the P-gp
efflux system leading to increased drug accumulation in the
MDR cells (Alakhov et al., 1996a,b). However, in contrast to
most known P-gp inhibitors, which usually increase MDR
cell sensitivity to the levels observed with non-MDR cells,
these copolymers hypersensitised the MDR cells. Therefore,Chemosensitising effects of copolymers
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Pluronic copolymers may be the most potent sensitisers of
MDR cancers, a unique feature of these delivery systems. The
chemosensitising effects of the Pluronic copolymers depended
critically on their hydrophobic-lipophilic balance (HLB)
(Alakhov et al., 1996a). This paper investigates anti-tumour
effects of doxorubicin (DOX) and epirubicin (EPI) formu-
lated with Pluronic L61, P85 and F108 copolymers with
varying hydrophobicity, using s.c. drug-sensitive and
-resistant murine myelomas Sp2/0 and Sp2/oDNR, and
leukaemia P388.
Materials and methods
Drug/copolymer compositions
Pluronic L61, P85 and F108 (abbreviated below as 'L61',
'P85' and 'F108' respectively) were purchased from Serva
(Germany) and used without further purification. They were
dissolved at various concentrations (0.1 to 1%) in phosphate-
buffered saline (PBS) at 4°C and then sterilised by filtration
through a 0.2 gm filter. Drug/copolymer compositions were
obtained by dissolving EPI (Farmitalia Carlo Erba, Milan,
Italy) or DOX (Farreign, Moscow, Russia) in the copolymer
solutions. These compositions were incubated for 30 min at
37°C before administration to mice.
Physicochemical characterisation of drug/copolymer
compositions
The critical micelle concentrations (CMCs) of L61, P85 and
F108 were determined using a pyrene solublisation technique
previously described by Kabanov et al. (1995). The
partitioning of anthracyclines in the micelles was studied by
fluorescence spectroscopy (Alakhov et al., 1996a). Briefly,
0.12 ,ug ml-1 of the drug was dissolved in copolymer
solutions of various concentrations, and the drug fluores-
cence spectra (4ex=471 nm) were recorded using a Shimadzu
500 spectrofluorimeter at 37°C. The partitioning coefficients,
P, were determined from the dependencies of drug
fluorescence at Aem = 547 nm on the copolymer concentration
using the linear plots:
Ima -I 100 - (1)
I -IO P. v.([Pluronic] - CMC) P
where Io is the fluorescence intensity in the absence of the
copolymer, I is the fluorescence at the given copolymer
concentration, Imax is the fluorescence at 'saturating'
concentration of the copolymer (when fluorescence reaches
the maximal value), [Pluronic] is the copolymer concentration
(% w/v) and v is the partial specific volume of the copolymer.
P-values determined using this technique were 200 for EPI
and DOX in P85, 330 for DOX in F108 and 10 000 for DOX
in L61.
Toxicity of copolymers
The acute toxicity of L61, P85 and F108 was studied on 7-
week-old C57B1/6 male mice obtained from Kriukovo
department of the nursery of the Russian Academy of
Medical Sciences. The animals were divided into groups
containing six animals each. Various doses of copolymers in
sterile PBS were administered intraperitoneally (i.p.). The
animal mortality in each group was monitored daily for 14
days. After 14 days the animals surviving to the end of the
experiment were sacrificed by cervical dislocation. The LD50
and MTD (i.e. the maximum dose that did not cause the
death of any animal in a treated group) were determined.
Tumour cells
All cell lines were cultivated in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS) at 37°C
and 5% carbon dioxide. Murine myeloma Sp2/0-Agl4
(ATCC CRL 8287) and P388 leukaemia cell lines were
obtained from the cell culture bank of the Russian Research
Center of Molecular Diagnostics and Therapy (Moscow,
Russia). The DNR-resistant Sp2/ODNR subline was obtained
from the Sp2/0 line by selection in increasing concentrations
(60-500 ng ml-1) of DNR. To maintain the resistance,
during each fourth passage, the Sp2/ODNR cells were
cultivated in the presence of 400 ng ml-' DNR.
In vitro cytotoxicity study
For the in vitro cytotoxicity test the Sp2/0 and Sp2/0DNR cells
were plated at 104 cells per well in 96-well plates (Costar,
Cambridge, MA, USA), and DNR solutions with or without
P85 (0.01%) were added to the cells (100 ,ul per well). Cells
were incubated with drugs for 4 days at 37°C and 5% carbon
dioxide. After that, the drug cytotoxic activity was evaluated
using the MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl
tetrazolium bromide) assay (Ferrari et al., 1990). All
experimental points were carried out in triplicate.
Effects on tumour growth
Approximately 3 x 106 tumour cells were implanted s.c. in
right inquinal region to 7-8-week-old female BALB/c mice
(Sp2/0 or Sp2/ODNR) or 4-5-week-old male BDF1 mice (P388)
obtained from Kriukovo department of the nursery of the
Russian Academy of Medical Sciences. After 10-14 (Sp2/0
or Sp2/0DNR) or 8 days (P388) since tumour implantation,
mice having solid tumours with an average volume between
150 and 300 mm3 were randomly allocated to groups
consisting of six animals each. The day of animal allocation
into groups was considered 'day 0' of the experiment. Drugs
were given i.v. on days 0, 4 and 8. Tumour weight, as derived
from caliper measurements of the length and width of
tumours, was calculated twice a week using the formula:
Tumour weight (mg) = 1/2 x a x b2 (2)
where a and b represent the length and the width (mm) of the
tumour respectively. The data were expressed in relative
weights (RW) calculated using the formula RW= Wi/Wo,
where Wi is the mean tumour weight at the beginning of
treatment, and Wi is the mean tumour weight at any
subsequent time. The tumour inhibition was determined on
days 14 (Sp2/0), 22 (Sp2/0N) and 11 (P388) using the
following formula (Shimomura et al., 1988):
TI(%) = (1 - RWT/RWC) x 100 (3)
where RWT and RWc are the relative weights in the treated
and control groups respectively. Both the RW and TI indexes
were considered not measurable if at least one animal in the
treated group died by the day of measurement. The statistical
significance of tumour inhibition data was analysed using the
Mann-Whitney U-test.
Effects on the lifespan
The median survival times in the treated and control groups
were determined and the T/C ratio was calculated as
follows:
T/C(%) = MSTT/MSTc x 100 (4)
where MSTT and MSTc are the mean survival times in the
treated and control groups respectively. Mice were observed
for 70 (Sp2/0), 60 (Sp2/0N) or 50 days (P388). The long-
term survival was attributed to animals surviving 70, 60 and
50 days respectively. Toxic death was recorded if it occurredChemosensitising effects of copolymers
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within the first 2 weeks after the first drug dose
administration. Differences in the lifespan of treated and
control animals were analysed for statistical significance using
single-tailed heteroscedastic t-test.
Activity criteria
The US National Cancer Institute criteria for anti-tumour
activity (Goldin et al., 1981; Dexter et al., 1985) were used.
Specifically, for the evaluation of the inhibition of tumour
growth 58 < TI<90, and TIk 90 were graded as 'moderate'
and 'good' activity respectively. For the evaluation of the
lifespan 120< T/C< 150, and T/C, 150 were considered as
'moderate' and 'good' activity respectively.
Results
Drug/Pluronic compositions
Three samples of Pluronic copolymers, specifically L61, P85
and F108, having a general structure formula:
CH3
HO H2CH20 CHCH2O---CH2CH20 H
m/2 n m/2
are investigated in this work. The lengths of hydrophilic PEO
(m) and hydrophobic PPO (n) segments in these copolymers
are varied. Copolymers with different m and n are
Table I Molecular parameters and critical micelle concentrations (CMCs) of Pluronic copolymers
CMC (%)
Copolymer Molecular mass m n HLBi (w/v)
Pluronic L61 1950 4-5 30 1-7 0.02
Pluronic P85 4500 51 39 12-18 0.03
Pluronic F108 16200 295 56 >24 0.03
aHLB was determined using gel permeation chromatography (BASF Performance Chemicals, Specialty Products, BASF Corporation, 1991).
Table II Drug/copolymer compositions and the fractions of micelle-incorporated drugs, a, in these compositions
atx 100 (%)'
Drug/copolymer Composition 1:1 1:10
EPI/P85 2mgml-1 EPI in 1% P85 in PBS 62.0 10.5
DOX/P85 lmgml-' DOX in 1% P85 in PBS 62.0 10.5
DOX/F108 lmgml-l DOX in 10% F108 in PBS 96.5 72.5
DOX/L61 (0.5%) 1 mgml-l DOX in 0.5% L61 in PBS 97.8 74.2
DOX/L61 (0.25%) 1mgml-' DOX in 0.25% L61 in PBS 95.7 32.6
DOX/L61 (0.1%) lmgmll DOX in 0.1% L61 in PBS 87.1 Below CMC
ao values were determined for the initial drug/copolymer compositions (1:1) and for the hypothetical conditions of 10-fold dilution of these
compositions in plasma (1:10).
Table III Anti-tumour effects of free drugs and drug/copolymer compositions on Sp2/0 murine myeloma
Drug Pluronic
dose dose
Drugs (mgkg'7) (mgkg'-) TD (%) LTS (%) TIC (%) Significancea
Free EPI 1.0 0 0 0 106 NS
2.0 0 0 0 107 NS
2.5 0 0 0 124 NS
5.0 0 0 0 95 NS
7.5 0 0 0 126 P=0.006
Free DOX 1.25 0 0 0 84 NS
2.5 0 0 0 83 NS
3.5 0 0 0 96 NS
5.0 0 16.7 0 81 NS
DOX/F108 2.0 200 0 0 80 P =0.005
3.5 350 0 33.3 118 NS
5.0 500 0 16.7 121 NS
EPI/P85 1.0 5 0 0 99 NS
2.0 10 0 0 102 NS
2.5 12.5 0 0 129 NS
5.0 25 0 0 130 P=0.0006
7.5 37.5 0 33.3 169 P=0.05
DOX/L61 (0.5%) 0.625 3.125 0 33.3 138 NS
1.25 6.25 0 0 155 P=0.01
2.5 12.5 0 0 138 P=0.006
5.0 25 16.7 33.3 106 NS
DOX/L61 (0.25%) 1 25b 3.125 0 0 145 NSc
2.5 6.25 0 50.0 180 P=0.004
5.0 12.5 33.3 0 61 -
DOX/L61 (0.1%) 2.5 2.5 0 16.7 127 P=0.04
3.5d 3.5 0 25.0 114 NS
I% P85e 0 100 0 0 94 NS
aMarked as not significant (NS) if P>0.05. bGroup of five animals. cClose to significant (P= 0.079). dGroup of four animals. eGroup of 11
animals. LTS, long-term survivors; TD, toxic death. Each treated groupcontained six animals, ifnotindicated otherwise. Themedian survival time
of the animals in the control group (n =31) was 31.9 (+ 13.4 s.d.).Chemosensitising effects of copolymers
EV Batrakova et at
1548
characterised by different HLB. The molecular parameters of
the copolymers used in this work are presented in Table I.
Hydrophobicity of the copolymers increases (HLB decreases)
in the following order: F108<P85<L61. Toxicity of the
copolymers in mice increases in the same order: F108
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Figure 1 Effects of free drug and drug/copolymer composition on the growth of (a-e) Sp2/0 and (f) P388 tumours. Animals were
treated with (a) EPI or EPI/P85; (b) DOX or DOX/L61 (0.5%); (c) DOX or DOX/L61 (0.25%); (d) DOX or DOX/L61 (0.1%); (e)
DOX or DOX/F108; (f) DOX or DOS/P85. The symbols correspond to control groups (+); corresponding copolymer in the
absence of drug (*); free drugs in doses of l0 mgkg-l (O), 7.5 mgkg-
I (0), 5 mgkg-
I (A), 3.5 mgkg- I (V? and 2.5 mgkg'- (O);
and drug/copolymer compositions in doses,of l0mgkg-l (l), 7.5 mgkg- I (0), 5 mgkg (A), 3.5 mgkg- (v), 2.5 mgkg- I (*)
and 1.25mgkg-' (x). The data are expressed in log of relative weights (RW) determined as described in Materials and methods.
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Ileast two to five times less than MTD. The resulting drug/
copolymer compositions are presented in Table II. In all
cases the concentrations of copolymers in the compositions
were significantly higher than the CMCs. Therefore, the
micelles were present in these systems along with the
equilibrium concentration of the single chains ('unimers') of
the copolymer (which approximates CMC). Further, in these
systems the drug molecules are partitioned between the
micellar microphase and bulk aqueous phase. The fraction of
the micelle-incorporated drug, a, is dependent on the
copolymer concentration and the partitioning coefficient
(Kabanov et al., 1995):
Cmic
Cc= C P([Pluronic] - CMC)
100. v-1 + (P - 1)([Pluronic] - CMC)
where C..,, and CO are the concentration of the micelle-
incorporated drug and the total concentration of the drug in
the system respectively. The P-values were determined for
various copolymers using fluorescence measurements as
described in Materials and methods. The values of a were
calculated using equation (5) for the initial drug/copolymer
compositions and for the hypothetical conditions of a 10-fold
dilution of these compositions in plasma (Table II).
Activity against s.c. Sp2/0 tumour
The data on the drug effects on the lifespan of mice with Sp2/
0 tumour are summarised in Table III. A dose of 7.5 mg kg-'
free EPI moderately increased the lifespan of the treated
group; the effects of the lower doses were insignificant, and
higher doses caused toxic death (not shown in Table III). The
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Figure 2 Lifespan distribution for mice with Sp2/0 tumour for
the control group (n=31,
I ) and groups (n=23, _) treated
with 1.25 and 2.5mgkg-' DOX/L61 (0.25%) and (0.5%).
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free DOX was ineffective in doses up to 3.5 mg kg-1, while
5.0 mg kg-' and larger doses caused toxic death. Further, TI
indexes, both for free EPI and DOX, did not exceed 17%
and were not statistically significant. In contrast to the free
drugs, several drug/copolymer compositions revealed good
activity in lifespan and tumour growth tests. Specifically,
EPI/P85 revealed good activity against Sp2/0 tumours at
7.5 mg kg-' and was moderately active at 5 mg kg-' (Table
III). In these cases the TI index was as high as 99.6% and
66.8%, respectively, with a level of significance of P<0.01.
Further, 33.3% of long-term survivors were observed in the
group treated with 7.5 mg kg-i EPI/P85. The kinetics of the
tumour growth presented in Figure la suggests that this dose
exhibited the highest anti-tumour effect causing the reversal
of the Sp2/0 growth at about 2 weeks after first
administration of the drug. About 2 weeks after the last
administration, relapse of the tumour was observed in four
animals, which accounted for the tumour volume elevation.
However, two -long-term survivors did not demonstrate
tumour relapse over the entire study period. Even more
pronounced effects were observed with DOX/L61 (0.5%) and
DOX/L61 (0.25%) compositions. In these cases substantial
activity was observed with 1.25 mg kg-' and 2.5 mg kg-'
doses. To illustrate the effects of these compositions on
lifespan, a histogram is presented in Figure 2 comparing the
lifespan of the control group and a combined group of
animals treated with 1.25 mg kg-' and 2.5 mg kg-' DOX/
L61 (0.5%) and DOX/L61 (0.25%). The survival time
distribution in the control group (n=31) is close to normal,
with the MSTc being 31.9 (± 13.4 s.d.). One animal in the
control group died on day 7, which for the treated group
would be considered as 'toxic' death; one animal was
considered as a long-term survivor. The significant increase
in the survival times in the combined treated group (n=23)
was observed, with MSTT being 49.4 (±14.0 s.d.), and T/
C= 155 (P= 1.7 x 10-5). Five animals in the combined treated
group qualified as long-term survivors, and no toxic death
was observed. The best effects on the lifespan were observed
in the individual groups treated with 2.5 mg kg-' DOX/L61
(0.25%). In the groups treated with 2.5 mg kg-' DOX/L61
(0.25%) and DOX/L61 (0.5%), the TI indexes were as high
as 99.4% and 98.0%, and the differences between tumour
volumes in the treated and control groups were statistically
significant (P<0.002). The kinetics of tumour growth in these
cases was similar to that observed for EPI/P85, revealing the
reversal of tumour growth with subsequent relapse after
interruption ofdrug administration (Figure 1 b and c). In the
case of 2.5 mgkg-' DOX/L61 (0.25%), three long-term
survivors were completely cured of the tumour. The effects of
DOX/L61 compositions were dependent on the copolymer
concentration. A dose of 2.5 mg kg-' DOX/L61 (0.1%)
revealed only moderate activity in the lifespan test (Table III)
and caused much less significant effects on tumour growth
compared with the effects of the compositions with higher
copolymer content (Figure ld). More modest effects
(compared with L61- and P85-based compositions) were
observed with DOX/F108. A dose of 2 mg kg-' DOX/F108
Table IV Anti-tumour effects of free drugs and drug/copolymer compositions on P388 murine leukaemia
Drug Pluronic
dose dose
Drugs (mgkg;-) (mgkg-') TD (%) LTS (%) TIC (%) Significance
Free DOX 0.25a 0 0 0 80 NS
2.5 0 0 16.7 116 NS
5 0 0 0 99 NS
10 0 0 16.7 138 NS
DOX/P85 0.25a 2.5 0 16.7 112 NS
2.5 25 0 16.7 105 NS
5 50 0 33.3 123 NS
10 100 0 33.3 152 P<0.016
1% P85b 0 100 0 0 102 NS
aGroup of four animals. bGroup of 12 animals. The median survival time of the animals in the control group (n=6) was 25.5 (±8.5 s.d.).
Abbreviations are the same as in TableIII.
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caused some decrease in the lifespan. The effects of
3.5 mg kg-' and 5.0 mg kg-' were not statistically signifi-
cant, and 7.5 mg kg-' (not shown in Table III) was toxic.
Nevertheless, 33.3% and 16.7% of long-term survivors were
observed with 3.5 mg kg-' and 5.0 mg kg-' DOX/F108
respectively. Further, the good activity in inhibition of
tumour growth (TI=92.2%, P<0.002) was observed with
the 5.0 mg kg-' dose of DOX/F108 (Figure le). Generally,
the effective dose range of drug/copolymer compositions was
lower compared with the free drug doses. However, the anti-
tumour activity of these compositions was higher than the
activity of the free drugs. These effects were evidently a result
of formulating the drugs with the copolymers since
copolymers alone did not significantly affect either the
median survival time or the tumour growth (Table III and
Figure 1).
Activity against s.c. P388 tumour
The effects of free drug and drug/copolymer on s.c. P388
were compared using the example of DOX and DOX/P85.
The effects of DOX on the lifespan (Table IV) and tumour
inhibition were not statistically significant. Nevertheless,
16.7% of long-term survivors were observed with
2.5 mg kg - and 10 mg kg doses. In the case of DOX/
P85, 16-33.3% of long-term survivors were observed with all
the doses studied. Further, significant activity was observed
with a 10 mg kg-1 dose of DOX/P85 using the lifespan test.
The significant deceleration of tumour growth was observed
with this dose (Figure I0), with the TI index approximating
91%.
Activity against s.c. Sp2/ODNR tumour
Incorporation of anthracyclines and other MDR-type drugs
in Pluronic compositions overcomes in vitro drug resistance
of MDR cancer cells (Alakhov et al., 1996a,b). In this work
we investigated the effects of drug/copolymers on DNR-
resistant Sp2/ODNR cells. This subline was selected from the
parental Sp2/0 line by DNR treatment. Using the MTT test,
it was shown that the Sp2/0DNR cells exhibited approximately
a 10-fold resistance to DNR compared with the parental line.
Table V In vitro cytotoxicity of DNR and DNR/P85 with respect
to drug-sensitive and -resistant murine myeloma
ICso (ngmrl')
Cell line DNR DNR/P85-
Sp2/0 130 70
Sp2/oDNR 1200 (700)b 50 (80)b
aP85 concentration equals 0.002%. bValues in parenthesis are the
IC50 determined for Sp2/oDNR grown in BALB/c mice s.c. for 7weeks
and then adapted to culture.
This resistance was reversed in the presence of P85 (Table V).
Further, the Sp2/0DNR tumour maintained the resistance
during the entire period of growth in mice (Table V). It
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Figure 3 Effects of free drug and drug/copolymer composition on
the growth of Sp2/0DNR tumour treated with (a) EPI or EPI/P85;
and (b) DOX or DOX/L61 (0.5%). The symbols correspond to
control groups (+); corresponding copolymer in the absence of
drug (*); free drugs in doses of 5mgkg-1 (A) and 2.5mgkg-1
(O$); and drug/copolymer compositions in doses of 5mgkg-
1 (A)
and 2.5mgkg-1 (*).
Table VI Anti-tumour effects of free drugs and drug/copolymer compositions on Sp2/ODNR murine myeloma
Drug Pluronic
dose dose
Drugs (mgkg-1) (mgkg'-) TD (%) LTS (%) TIC (%) Significance
Free EPI 1.0 0 0 0 100 NS
5.0a 0 0 0 83 NS
7.5 0 0 0 77 NS
Free DOX 2.5 0 0 0 80 NS
5.0 0 0 0 81 NS
EPI/P85 1.0 5 0 16.7 122 P=0.01
50b 25 0 0 90 NS
DOX/L61 (0.5%) 2.5 12.5 0 0 86 NS
5.0 25 0 0 93.4 NS
1% P85 0 100 0 0 111 NS
0.5% L61 0 50 0 0 81 NS
aGroup of four animals. bGroup of five animals. The median survival time of the animals in the control group (n = 17) was 44.5 (+ 13.6 s.d.).
Abbreviations are the same as in Table III.
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should be noted, however, that 5 mg kg-' free DOX and EPI
revealed inhibition of tumour growth in vivo (TI of 45% and
41% respectively), which was higher than the effects of these
drugs on the parental Sp2/0 tumour. The growth rate of Sp2/
0DNR was 2-5 times lower than that of Sp2/0, which may
explain why the free drug was more active against Sp2/0DNR
tumour in vivo. The effects of the free drugs and drug/
copolymer compositions on the lifespan were not significant
with the exception of 1.0 mg kg-' EPI/P85, which revealed
moderate activity in this test (Table VI). However, the effects
of this composition on tumour growth were moderate (Figure
3a), with the TI index (=54%) barely exceeding that
observed with the free drug. The best results on tumour
inhibition were observed with DOX/L61 (0.5%). As shown in
Figure 3a, reversal of tumour growth was observed with
2.5 mg kg-' and 5 mg kg-' ofthis composition, yielding a TI
index approximating 90% (P<0.01).
Discussion
One major result of this work is that Pluronic copolymers
significantly increase the anti-tumour effects of anthracycline
antibiotics in vivo observed in conditions of high tumour
inoculum. Contrary to previous observations with DOX that
was covalently attached to a block copolymer carrier
(Yokoyama et al., 1990, 1991), the effective doses of non-
covalently incorporated anthracyclines were the same or
lower than those of the free drugs. Furthermore, the increase
in the lifespan and inhibition of tumour growth were
observed with the effective doses of drug/copolymer
compositions. Given the amount of compositions involved
in this study, as well as the dependence of their activity on
several factors, it is likely that the anti-tumour effects can be
further improved by optimising the type of copolymer, its
concentration as well as administration schedule. Never-
theless, based on the data of Sp2/0 myeloma, one can make a
preliminary assumption that higher activity in inhibition of
tumour growth is associated with more hydrophobic
copolymers. Specifically, the EPI/P85 and DOX/L61 compo-
sitions were very active in the lifespan and tumour inhibition
tests.
One concern about drugs conjugated to block copolymers
is their slow or insignificant release from the polymeric
carrier (M Yokoyama, personal communication). The
situation is totally different in the case of the non-covalent
compositions studied in this paper. Indeed, in these systems
both the block copolymer and drug molecules are partitioned
and dynamically exchanged between the bulk aqueous phase
and micelle species (Kabanov et al., 1995; Alakhov et al.,
1996a). The equilibrium partitioning of the copolymer is
characterised by the CMC: above this concentration both the
micelles and the unimers of the copolymer are present in the
system. The drug molecules are also partitioned between the
micelles and bulk aqueous phase, with the fraction of the
micelle-incorporated drug expressed by equation (5). Two
major conclusions can be made based on this consideration.
First, if the drug-containing micelles accumulate in the target
tissue then they would serve as a 'depot' for the release of the
free drug, which does not involve cleavage of the chemical
bonds between drug and copolymer. This underlies a major
difference between non-covalent formulations and the drugs
conjugated to the polymers, where the release of the drug
from the carrier in the active state requires its cleavage into
the target cell (Subr et al., 1992). Second, the dilution of the
copolymer micelles in the body fluids must lead to the
decrease in the fraction of the drug micellar form and
increase in the free drug form respectively. For example, the
data presented in Table II suggest that 10-fold dilution of
DOX/L61 (0.1%) would result in decrease of the L61
concentration below CMC and, thus, eliminate the micelles
from circulation. The same dilution would preserve the
micelles in the case of DOX/L61 (0.25%) and (0.5%), which
will still retain substantial portions of the drug. It is possible
that dilution effects contribute to the dependence of the anti-
tumour effects on the drug concentration. This consideration,
however, does not account for the possible effects of the
copolymer structure on the pharmacokinetics and biodistri-
bution picture. It was previously demonstrated that the
biodistribution of the fluorescent dye incorporated in
Pluronic micelles was strongly dependent on copolymer
structure (Kabanov et al., 1992). Therefore, the molecular
parameters of the copolymers may cause complex effects on
drug performance and result in the differences in anti-tumour
activities exhibited. The study of these effects is currently in
progress in our laboratories.
Acknowledgements
The authors would like to thank Dr EY Moskaleva and Dr IA
Trusova for assistance in cell experiments, Dr T Ludden and K
Ryschon for the advice on statistical analysis of the data, and Dr P
Gwilt for valuable comments. The work in Moscow was in part
supported by Supratek Pharma Inc. (Montreal, Canada). The
work on drug partitioning in the micelles was supported by the
Nebraska Research Initiative.
References
ALAKHOV V YU, BATRAKOVA EV, DORODNICH T, LI S, VENNE A
AND KABANOV AV. (1996a). Block copolymeric drug carriers: 1.
delivery of antineoplstic drugs. In Abstracts ofFirst International
Symposium on Polymer Therapeutics. p. 213. The School of
Pharmacy, University of London: London, UK.
ALAKHOV V YU, MOSKALEVA E YU, BATRAKOVA EV AND
KABANOV AV. (1996b). Reversion of multidrug resistance of
human ovarian carcinoma cells by Pluronic P85 block copolymer.
Bioconj. Chem., 7, 209-216.
ALEXANDRIS P, HOLZWARTH JF AND HATTON TA. (1994).
Micellization of poly(ethylene oxide)-poly(propylene oxide)
triblock copolymers in aqueous solutions: thermodynamcis of
copolymer association. Macromeolecules, 27, 2414-2425.
BADER H, RINGSDORF H AND SCHMIDT B. (1984). Water soluble
polymers in medicine. Angew. Makromol. Chemie., 123/124, 457-
483.
DEXTER DL, HESSON DP, ARDECKY RJ, RAO GV, TIPPETT DL,
DUSAK BA, PAULL KD, PLOWMAN J, DELARCO BM, NARAYA-
NAN VL AND FORBES M. (1985). Activity of a novel 4-
quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-
1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium
salt], against experimental tumors. Cancer Res., 45, 5563 -5568.
DOUGHTY JC, ANDERSON JH, WILLMOTT N AND MCARDLE CS.
(1995). Intra-arterial administration of adriamycin-loaded
albumin microspheres for locally advanced breast cancer.
Postgrad. Med. J., 71, 47-49.
DRAPER M, SAVAGE M, COLLET JH, ATTWOOD D, PRICE C, BOOTH
C AND WANG Q-G. (1995). Solubilization of drugs in micellar
systems studied by eluent gel permeation chromatography.
Pharm. Res., 12, 1231-1237.
DUNCAN R. (1992). Drug-polymer conjugates: potential for
improved chemotherapy. Anti-Cancer Drugs, 3, 175-210.
DUNN SE, BRINDLEY A, DAVIS SS, DAVIES MC AND ILLUM L.
(1994). Polystyrene-poly(ethylene glycol) (PS-PEG20000) parti-
cles as model systems for site specific drugdelivery. 2. The effect of
PEG surface density on the in vitro cell interaction and in vivo
biodistribution. Pharm. Res., 11, 1016- 1022.
FERRARI M, FORNASIERO MC AND ISETTA AM. (1990). MTT
colorimetric assay for testing macrophage cytotoxic activity in
vitro. J. Immunol. Methods, 131, 165-172.
GABIZON A. (1993). Tailoring liposomes for cancer drug delivery:
from the bench to the clinic. Ann. Biol. Clin. Paris, 51, 811 -813.Chemosensitising effects of copolymers
EV Batrakova et al
1552
GOLDIN A, VENDITTI JM, MACDONALD JS, MUGGIA FM, HENNEY
JE AND DEVITA JR VT. (1981). Current results of the screening
program at the division of cancer treatment, National Cancer
Institute. Eur. J. Cancer, 17, 129- 142.
KABANOV AV, CHEKHONIN VP, ALAKHOV V Yu, BATRAKOVA EV,
LEBEDEV AS, MELIK-NUBAROV NS, ARZHAKOV SA, LEVA-
SHOV AV, MOROZOV GV, SEVERIN ES AND KABANOV VA.
(1989). The neuroleptic activity of haloperidol increases after its
solubilization in surfactant micelles. Micelles as microcontainers
for drug targeting. FEBS Lett., 258, 343-345.
KABANOV AV, BATRAKOVA EV, MELIK-NUBAROV NS, FEDOSEEV
NA, DORODNICH T Yu, ALAKHOV V Yu, CHEKHONIN VP,
NAZAROVA IR AND KABANOV VA. (1992). A new class of drug
carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block
copolymers as microcontainers for drug targeting from blood in
brain. J. Contr. Release, 22, 141-158.
KABANOV AV, NAZAROVA IR, ASTAFIEVA IV, BATRAKOVA EV,
ALAKHOV V Yu, YAROSLAVOV AA AND KABANOV VA. (1995).
Micelle formation and solubilization of fluorescent probes
in poly(oxyethylene-b-oxypropylene-b-oxyethylene) solutions.
Macromolecules, 28, 2303-2314.
KWON G, NAITO M, YOKOYAMA M, OKANO T, SAKURAI Y AND
KATAOKA K. (1993). Micelles based on AB block copolymers of
poly(ethylene oxide) and poly(,B-benzyl L-aspartate). Langmuir, 9,
945-949.
KWON GS, NAITO M, YOKOYAMA M, OKANO T, SAKURAI Y AND
KATAOKA K. (1995). Physical entrapment of adriamycin in AB
block copolymer micelles. Pharm. Res., 12, 192- 195.
LA SB, OKANO T AND KATAOKA K. (1996). Preparation and
characterization of the micelle-forming polymeric drug. Indo-
methacin-incorporated poly(ethylene oxide)-poly(b-benzyl L-
aspartate) block copolymer micelles. J. Pharm. Science, 85, 85-
90.
MAEDA H, SEYMOUR LW AND MIYAMOTO Y. (1992). Conjugates
of anticancer agents and polymers: advantages of macromole-
cular therapeutics in vivo. Bioconj. Chem., 3, 351 -362.
MAYER LD, MASIN D, NAYAR R, BOMAN NL AND BALLY MB.
(1995). Pharmacology of liposomal vincristine in mice bearing
L1210 ascitic and B16/BL6 solid tumors. Br. J. Cancer, 71, 482-
488.
REILLY RM, SANDHU J, ALVARES-DIEZ TM, GALLINGER S, KIRSH
J AND STERN H. (1995). Problems of delivery of monoclonal
antibodies. Pharmaceutical and pharmacokinetic solutions. Clin.
Pharmacokin., 28, 126- 142.
SHIMOMURA K, MANDA T, MAKUMOTO S, MASUDA K, NAKA-
MURA T, MIZOTA T, MATSUMOTO S, NISHIGAKI F, OKU T,
MORI J AND SHIBAYAMA F. (1988). Antitumor activity and
hematoxicity ofa new, substituted dihydrobenzoxazine FK973, in
mice. Cancer Res., 48, 1166-1172.
SUBR V, STROHALM J, ULBRICH K, DUNCAN R AND HUME IC.
(1992). Polymers containing enzymatically degradable bonds.
XII. Effect of spacer structure on the rate of release of
daunomycin and adriamycin from poly[N-(2-hydroxypropyl)-
methacrylamide] copolymer drug carriers in vitro and antitumor
activity measured in vivo. J. Contr. Rel., 18, 123- 132.
TORCHILIN VP, OMELYANENKO VG, PAPISOV MI, BOGDANOV AA
JR, TRUBETSKOY VS, HERRON JN AND GENTRY CA. (1994).
Poly(ethylene glycol) on the liposome surface: on the mechanism
of polymer-coated liposome longevity. Biochim. Biophys. Acta,
1195, 11-20.
TRUBETSKOY VS, TORCHILIN VP, GAZELLE GS AND WOLF GL.
(1994). Amphiphilic radiopaque iodine-containing block-copoly-
mer as micellar polymeric carrier with controlled in vivo
performance. Proc. Intern. Symp. Control. Rel. Bioact. Mat., 21,
676-677.
YOKOYAMA M, MIYAUCHI M, YAMADA N, OKANO T, SAKURAI,
Y, KATAOKA K AND INQUE S. (1990). Characterization and
anticancer activity of the micelle-forming polymeric anticancer
drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic
acid) block copolymer. Cancer Res., 50, 1693- 1700.
YOKOYAMA M, OKANO T, SAKURAI Y, EKIMOTO H, SHIBAZAKI C
AND KATAOKA K. (1991). Toxicity and antitumor activity
against solid tumors of micelle-forming polymeric anticancer
drug and its extremely long circulation in blood. Cancer Res., 51,
3229-3236.